A new study has shown that on average, 70% of eczema patients are colonised with Staphylococcus aureus bacteria on their skin lesions (which include MRSA). Could this the Dutch biotech Micreos therefore have the solution to preventing spread of antibiotic-resistant strains in Eczema patients?
Atopic dermatitis (eczema) is an extremely common skin affliction which can cause in painful lesions, which are open to infection and difficult to manage.
It has a variety of suspected causes, many of which are chemical based (such as excessive hand-washing in the Food industry and hospitals). However, this new research has put some surprising statistics behind a potentially less obvious suspect – strains of Stapylococcus aureus, which can include methicillin-resistant types (MRSA).
In a study published in the British Journal of Dermatology, up to 80% of patients with eczema were found to have a strain of Staphylococcus which produced a toxin. Toxins produced from certain strains are irritating to the skin,